EpiCept Corporation Files for AmiKet™ Fast Track Designation
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today announced that it has filed for Fast Track designation for AmiKet™ (amitriptyline 4%, ketamine 2% cream) for the treatment for chemotherapy-induced peripheral neuropathy (CIPN) with the U.S. Food and Drug Administration (FDA). AmiKet™ is a prescription topical cream under late stage clinical development by EpiCept for the treatment of peripheral neuropathic pain.
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today announced that it has filed for Fast Track designation for AmiKet™ (amitriptyline 4%, ketamine 2% cream) for the treatment for chemotherapy-induced peripheral neuropathy (CIPN) with the U.S. Food and Drug Administration (FDA). AmiKet™ is a prescription topical cream under late stage clinical development by EpiCept for the treatment of peripheral neuropathic pain.